

Loxl3 Cas9-CKO Strategy


Designer: Lingyan Wu

Reviewer: Miaomiao Cui

Design Date: 2021-3-31

Project Overview






江苏集萃药康生物科技股份有限公司

GemPharmatech Co., Ltd.

Conditional Knockout strategy

第二本 集萃药康 GemPharmatech

This model will use CRISPR/Cas9 technology to edit the Lox13 gene. The schematic diagram is as follows:



江苏集萃药康生物科技股份有限公司

GemPharmatech Co., Ltd.

Technical routes



The Lox13 gene has 5 transcripts. According to the structure of Lox13 gene, exon3-exon4 of Lox13-201(ENSMUST0000000707.9) transcript is recommended as the knockout region. The region contains 379bp coding sequence. Knock out the region will result in disruption of protein function.

➤ In this project we use CRISPR/Cas9 technology to modify *Lox13* gene. The brief process is as follows:CRISPR/Cas9 system and Donor were microinjected into the fertilized eggs of C57BL/6JGpt mice.Fertilized eggs were transplanted to obtain positive F0 mice which were confirmed by PCR and sequencing. A stable F1 generation mouse model was obtained by mating positive F0 generation mice with C57BL/6JGpt mice.

> The flox mice will be knocked out after mating with mice expressing Cre recombinase, resulting in the loss of function of the target gene in specific tissues and cell types.



- > According to the existing MGI data, mice homozygous for a knock-out allele exhibit lethality shortly after birth, craniofacial and vertebral abnormalities associated with collagen deformities.
- The *Loxl3* gene is located on the Chr6. If the knockout mice are crossed with other mice strains to obtain double gene positive homozygous mouse offspring, please avoid the two genes on the same chromosome.
 This strategy is designed based on genetic information in existing databases Due to the complexity of biological
- > This strategy is designed based on genetic information in existing databases.Due to the complexity of biological processes,all risk of loxp insertion on gene transcription, RNA splicing and protein translation cannot be predicted at existing technological level.

Gene information (NCBI)



< ?

LoxI3 lysyl oxidase-like 3 [Mus musculus (house mouse)]

Gene ID: 16950, updated on 13-Mar-2020

Summary

Official SymbolLoxl3 provided by MGIOfficial Full Namelysyl oxidase-like 3 provided by MGIPrimary sourceMGI:MGI:1337004See relatedEnsembl:ENSMUSG0000000693Gene typeprotein codingRefSeq statusVALIDATEDOrganismMus musculusLineageEukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha;
Muroidea; Murinae; Mus; MusAlso known asLor2, Loxl2ExpressionUbiquitous expression in limb E14.5 (RPKM 18.2), bladder adult (RPKM 8.2) and 28 other tissues
See more

江苏集萃药康生物科技股份有限公司

GemPharmatech Co., Ltd.


Transcript information (Ensembl)



The gene has 5 transcripts, all transcripts are shown below:


Name	Transcript ID	bp	Protein	Biotype	CCDS	UniProt	Flags
Lox13-201	ENSMUST0000000707.8	4098	<u>754aa</u>	Protein coding	CCDS20266	<u>Q9Z175</u>	TSL:1 GENCODE basic APPRIS is a system to annotate alternatively spliced transcripts based on a range of computational methods to identify the most functionally important transcript(s) of a gene. APPRIS P1
Lox13-202	ENSMUST0000101257.3	3252	<u>472aa</u>	Protein coding		E9Q0X7	TSL:1 GENCODE basic
Lox13-205	ENSMUST00000204318.1	617	No protein	Processed transcript	-	-	TSL:5
LoxI3-203	ENSMUST00000152679.7	462	No protein	Processed transcript	2	25	TSL:2
Lox13-204	ENSMUST00000155502.1	611	No protein	Retained intron	-	51	TSL:5

The strategy is based on the design of *Loxl3-201* transcript, the transcription is shown below:



Genomic location distribution






江苏集萃药康生物科技股份有限公司

GemPharmatech Co., Ltd.

Protein domain






江苏集萃药康生物科技股份有限公司

GemPharmatech Co., Ltd.

Mouse phenotype description(MGI)



Phenotypes affected by the gene are marked in blue. Data quoted from MGI database(http://www.informatics.jax.org/).

According to the existing MGI data, mice homozygous for a knock-out allele exhibit lethality shortly after birth, craniofacial and vertebral abnormalities associated with collagen deformities.

江苏集萃药康生物科技股份有限公司

GemPharmatech Co., Ltd.



If you have any questions, you are welcome to inquire. Tel: 400-9660890



